For efficient immune detection, neoantigens generated from non‐synonymous DNA base changes must first be shown on MHC‐I or MHC‐II molecules, followed by recognition by peptide‐specific T cell receptors (TCRs).[76, 77] Taken together, we concluded that sufficient delivery of tumor neoantigens to CD8+ Trm cells to initiate its development into anti‐tumoral effector T cells is essential for the ICB response. The gene discussed is CD8A; the disease is neoplasm.